AVILEX PHARMA ApS: Financial statements 2022
CVR: 34896828
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
AVILEX PHARMA ApS (CVR 34896828) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 45,479,000 and a net result of DKK 28,600,000 compared with DKK -6,611,177 the year before. The profit margin was 62.9%. Equity in the 2022 report amounted to DKK 4,917,000. The solvency ratio was 15.6%. The company had 2 employees in the financial year.
- Revenue
- DKK 45,479,000
- Gross Profit
- DKK 45,479,000
- Profit/Loss
- DKK 28,600,000
- Equity
- DKK 4,917,000
- Total Assets
- DKK 31,591,000
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 45.5 mio. | 45.5 mio. | 28.6 mio. | 4.9 mio. | 2 |
| 2021 | - | - | -6.6 mio. | -25.3 mio. | 2 |
| 2020 | - | -3.1 mio. | -3 mio. | -18.6 mio. | 2 |
| 2019 | - | - | -3.7 mio. | -15.6 mio. | 4 |
| 2018 | - | - | -3.9 mio. | -11.9 mio. | 1 |
Official annual report
Keep an eye on AVILEX PHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of September 23, 2022, Novo Holdings A/S is registered as an owner of AVILEX PHARMA ApS with an ownership share of 50%.
As of August 31, 2022, EY Godkendt Revisionspartnerselskab has been appointed auditor of AVILEX PHARMA ApS.
As of August 31, 2022, Beierholm Godkendt Revisionspartnerselskab has stepped down as auditor of AVILEX PHARMA ApS.
AVILEX PHARMA ApS has published its annual report for 2021. The net result was DKK -6,611,177.
About AVILEX PHARMA ApS
AVILEX PHARMA ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristian Strømgaard. The board consists of Raymond George Hill (chair), Camilla Petrycer Hansen, Jonathan Mark Treherne and Kristian Strømgaard. The company's owners include Novo Holdings A/S, MIKAEL SØNDERGÅRD THOMSEN ApS and KRISTIAN STRØMGAARD HOLDING ApS. The company has 4 employees (2025). In 2025, the company reported a net result of DKK -4,530,000 compared with DKK -4,428,000 the year before. Equity in the 2025 report amounted to DKK -10,797,000.